MEDINCELL Stock: Strong Weekly Momentum Following Uzedy's Expanded Indication
This week, Medincell's stock stood out at the top of the SBF 120 with significant growth. The lab's technology benefited from a major regulatory endorsement in the United States, heightening interest in the stock. This movement is part of an already favorable context for the biotechnology sector.
Weekly Performance Overview
Medincell's stock closed the week at €33.90, up 18.37% over the analyzed period. Throughout the last five sessions, the stock showed a generally positive daily trend, with notable gains at the beginning of the week (+21.06% to €33.22 on Monday), followed by consolidations and slight fluctuations. This momentum was supported by particularly high trading volumes, exceeding 590,000 during the busiest sessions, indicating a resurgence of activity in the stock. Medincell has shown an annual performance of 121%, far outpacing benchmark indices like the CAC 40 (+1.65% this week) or the SBF 120 (+1.35%), highlighting its unique stock market trajectory in both the short and long term.
Regulatory Approval Fuels Surge
The acceleration in Medincell's stock rise directly stems from the green light given by the U.S. Food and Drug Administration (FDA) for the expanded indication of Uzedy, now approved for the treatment of type I bipolar disorder in adults. This innovation targets a significant population in the United States, estimated at 3.4 million people affected by this disorder in their lifetime. The commercial prospects for Uzedy have also seen a substantial increase: partner Teva has raised its annual sales target from $160 million to nearly $200 million, supported by a promising U.S. launch. In the short term, these developments could bolster royalty revenues and energize the laboratory's future growth.
Technical Perspective on Stock Performance
From a technical standpoint, the stock is now trading at its annual highs, having reached €34.38 in session, well beyond its 50-day and 200-day moving averages set at €21.95 and €16.92 respectively. The rapid progression of the stock price brings it close to the resistance threshold identified at €33.90, while monthly volatility remains high at around 20. The RSI has reached 87, indicating the strength of the movement, while the MACD line displays elevated levels, confirming the momentum initiated several weeks ago. These elements reflect a persistent enthusiasm around the stock, against a backdrop of major regulatory and commercial announcements. The upper Bollinger band, located at €35.50, frames this bullish movement, while the nearest support remains distant at €18.01.
